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A Brg1 mutation that uncouples ATPase
activity from chromatin remodeling
reveals an essential role for
SWI/SNF-related complexes in -globin
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The Brg1 catalytic subunit of SWI/SNF-related complexes has been implicated in many developmental and
physiological processes, but null homozygotes die as blastocysts prior to implantation. To circumvent this
early embryonic lethality, we performed an ENU mutagenesis screen and generated a Brg1 hypomorph
mutation in the ATPase domain. The mutant Brg1 protein is stable, assembles into SWI/SNF-related
complexes, and exhibits normal ATPase activity but is unable to establish DNase I hypersensitivity sites
characteristic of open chromatin. Mutant embryos develop normally until midgestation but then exhibit a
distinct block in the development of the erythroid lineage, leading to anemia and death. The mutant Brg1
protein is recruited to the -globin locus, but chromatin remodeling and transcription are perturbed. Histone
acetylation and DNA methylation are also affected. To our knowledge, Brg1 is the first chromatin-modifying
factor shown to be required for -globin regulation and erythropoiesis in vivo. Not only does this mutation
establish a role for Brg1 during organogenesis, it also demonstrates that ATPase activity can be uncoupled
from chromatin remodeling.
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Sequence-specific transcription factors are necessary,
but usually not sufficient, to regulate the transcription of
downstream target genes because the RNA Polymerase II
(Pol II) holoenzyme cannot access DNA in the context of
nucleosomes or higher-order chromatin structures
(Struhl 1999; Lemon and Tjian 2000). However, transcrip-
tional activators bound to enhancers or promoters can
recruit chromatin-modifying complexes, which cova-
lently modify N-terminal histone tails or utilize ATPase
activity to alter the conformation and/or position of
nucleosomes (Fry and Peterson 2001; Narlikar et al.
2002). As a result, these promoters adopt an “open” chro-
matin configuration capable of binding Pol II so that
transcription can be initiated. Conversely, transcrip-
tional repressors can recruit similar or identical com-
plexes to other loci to establish a “closed” chromatin
configuration that precludes transcription.
The Saccharomyces cerevisiae SWI/SNF complex,
which was one of the first chromatin-modifying com-
plexes to be identified, consists of 11 subunits with a
total molecular mass of ∼1 MDa (Sudarsanam and Win-
ston 2000; Smith et al. 2003; Mohrmann and Verrijzer
2005). After being recruited to a specific regulatory ele-
ment, the SWI2/SNF2 catalytic subunit hydrolyzes tens
to hundreds of ATP molecules per minute, thus enabling
the complex to break DNA–histone contacts, slide his-
tone octamers to alternate positions, and activate or re-
press ∼300 genes (Holstege et al. 1998; Sudarsanam et al.
2000). Conserved throughout metazoan evolution, SWI/
SNF-related complexes have been characterized in Dro-
sophila melanogaster and mammals. In Drosophila, the
catalytic subunit is called brahma (brm), which is the
Hindi word meaning “fate”, because mutations perturb
the expression of homeotic genes and cause homeotic
transformations (Tamkun et al. 1992; Tamkun 1995).
The biochemical composition and function of SWI/
SNF-related complexes are more varied in mammals
(Mohrmann and Verrijzer 2005). Duplication and diver-
gence events during vertebrate evolution resulted in an
increased number of SWI/SNF-related gene products,
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leading to subunit diversity in various mouse tissues and
human cell lines. For example, mammalian complexes
utilize either the brahma (Brm) or brahma-related gene 1
(Brg1) catalytic subunits, but not both (Wang et al. 1996).
Interestingly, despite having similar sequences (75%
identity at the amino acid level), in vitro activities, and
widespread expression, gene targeting experiments have
demonstrated that Brm is dispensable in mice (Reyes et
al. 1998), whereas Brg1 is essential (Bultman et al. 2000).
In fact, Brg1 is required for development beyond the
peri-implantation stage of early embryogenesis. Null
mutations of Baf155 or Baf47/Snf5, both of which en-
code integral components of Brm- and Brg1-contain-
ing complexes, also confer peri-implantation lethality
(Klochendler-Yeivin et al. 2000; Roberts et al. 2000;
Guidi et al. 2001; Kim et al. 2001). One possible expla-
nation for such a marked difference in phenotypic sever-
ity is that Brm- and Brg1-containing complexes might be
recruited to different downstream target genes. Indeed,
the N termini of Brm and Brg1 are divergent and physi-
cally interact with different transcription factors in
vitro. Brm associates with ankyrin repeats of factors in
the Notch pathway, whereas Brg1 associates with zinc-
finger transcription factors (Kadam and Emerson 2003).
To achieve a better understanding of the mechanism
and developmental role of mammalian SWI/SNF-related
complexes, a number of issues must be addressed. First,
although Brg1 ATPase activity is crucial, it is not clear
how the energy of ATP hydrolysis is harnessed to re-
model nucleosomes. Second, these complexes have been
implicated in a number of developmental and physi-
ological processes, but functional data have been lacking
because null homozygotes die at such an early stage of
embryogenesis. Third, chromatin-remodeling properties
have been described using artificial nucleosome arrays in
vitro, but mechanistic studies have not been performed
at physiologically relevant sites in vivo. Therefore, it is
not known whether SWI/SNF-related complexes also af-
fect covalent histone modifications or DNA methylation
at these sites during remodeling.
Here we describe the isolation and characterization of
an N-ethyl-N-nitrosourea (ENU)-induced Brg1 mutation
that addresses all of the issues listed above. This partial
loss-of-function mutation changes a single amino acid
residue (E1083G) in a highly conserved region of the
catalytic ATPase domain. The mutant protein is stable,
assembles into SWI/SNF-related complexes, and exhibits
normal ATPase activity, but its nucleosome remodeling
properties are diminished. Mutant embryos develop nor-
mally until midgestation, but then exhibit a distinct
block in the development of the erythroid lineage, lead-
ing to anemia and death. Mutant Brg1 complexes are
recruited to the -globin locus control region (LCR), but
chromatin remodeling and expression are significantly
reduced. Both histone acetylation and DNA methylation
are also affected in vivo.
Results
A novel Brg1 hypomorph allele
To circumvent the early embryonic lethality of Brg1null
homozygotes, we isolated a novel Brg1 hypomorph allele
in an ENU mutagenesis screen. We performed this
screen by exploiting a visible, recessive marker, called
curly whiskers (cw), that is tightly linked to Brg1 and a
microsatellite marker (D9Mit59) on proximal chromo-
some 9 (Fig. 1). cw/cw mice are viable and fertile but
Figure 1. Brg1 ENU mutagenesis screen.
The mutagenesis and breeding strategy
that was implemented is outlined by show-
ing a schematic of mouse chromosome 9
with the position of curly whiskers (cw),
Brg1, and D9Mit59 loci. Genetic distances
are indicated in centimorgans (cM) in the
top right panel. cw/cw males (top right)
were mutagenized (ENU) and bred to wild-
type females (top left). (Middle right) G1
progeny inherited one wild-type chromo-
some 9 from the dam and one muta-
genized cw chromosome 9 from the sire.
(Middle left) G1 specimens were mated to
a tester stock to determine which, if any,
carried a Brg1 mutation (Brg1ENU). (Bottom)
In the absence of a Brg1ENU mutation, G2
progeny fell into four equally represented
genotypic classes. (Bottom right) However,
inheritance of a Brg1ENU mutation that
failed to complement Brg1null would result
in underrepresentation or loss of the curly
whisker class (enclosed by a thick box).
(Bottom, second from left) In this case, the
Brg1ENU mutation could be recovered in
carriers (enclosed by a thin box).
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have curly vibrissa (Falconer and Isaacson 1966). In the
first step of this screen, cw/cw males were mutagenized
and bred to wild-type females. Five hundred twenty-five
G1 progeny were recovered. Each one inherited a wild-
type chromosome 9 from the dam and a mutagenized cw
chromosome 9 from the sire. The second step of this
screen was designed to identify which, if any, G1 progeny
carried a Brg1 mutation (Brg1ENU). Toward this end, ev-
ery G1 specimen was bred to a tester stock that had a
wild-type chromosome 9 balanced with a cw, Brg1null,
D9Mit59L haplotype. The G2 progeny were expected to
fall into four equally represented genotypic classes
unless a Brg1ENU mutation was inherited that failed
to complement Brg1null. In this case, the cw/cw class
would be underrepresented (<25%) or completely miss-
ing. Therefore, we scored whiskers of neonatal pups from
all 525 pedigrees. Collectively, 2033 out of 8774 G2 prog-
eny were cw/cw. However, no cw/cw pups were ob-
tained for one pedigree after 83 G2 progeny were scored
from eight litters (Supplementary Table 1). This
Brg1ENU1 mutation was recovered in carriers, which
were identified as normal whiskered G2 mice with a
D9Mit59U/L genotype not carrying the Brg1null allele, as
determined by PCR genotyping.
Brg1+/ENU1 carriers were bred to the tester stock to
confirm that the mutation was heritable and to deter-
mine when Brg1null/ENU1 mutants die. The cw marker is
not informative before birth so Brg1null/ENU1 mutant em-
bryos were identified by PCR as D9Mit59L/L. We recov-
ered mutants at each stage of development but observed
midgestation lethality based on lack of a heartbeat. Le-
thality started at embryonic day 11.5 (E11.5), nearly half
were dead at E12.5, and every mutant was dead by E14.5
(Supplementary Table 1). The orientation of these
crosses was not a factor, which is consistent with Brg1
not being imprinted. The fact that Brg1null/ENU1 embryos
survived much longer than Brg1null/null embryos
(midgestation compared with peri-implantation, respec-
tively) indicated that Brg1ENU1 is a hypomorph (i.e., par-
tial loss-of-function) allele.
Molecular and biochemical nature of the Brg1ENU1
mutation
One advantage of ENU mutagenesis is that point muta-
tions are induced, which provide valuable structure–
function correlations. To identify the molecular nature
of the Brg1ENU1 lesion, we performed RT–PCR on wild-
type (i.e., the C57BL/10 genetic background carrying cw
that was mutagenized) and mutant tissues and se-
quenced full-length Brg1 cDNA products. A single
adenosine-to-guanine transition was identified in exon
23 that changes the corresponding amino acid sequence
from a glutamic acid (E) to a glycine (G) (Fig. 2A). The
fact that this E1083G substitution is deleterious was not
surprising because a negatively charged residue in a
highly conserved segment of the ATPase domain, be-
tween putative helicase motifs IV and V, was converted
to an uncharged polar residue (Fig. 2B). The position and
hypomorphic nature of this substitution is informative
because a K-to-A change two amino acids upstream of
this residue in yeast SWI2/SNF2 was shown to be a null,
whereas a D-to-A change three positions downstream
had little or no phenotypic effect (Richmond and Peter-
son 1996).
The Brg1ENU1 mutation did not affect mRNA or pro-
tein stability based on Northern blot and Western blot
analyses, respectively (Fig. 3A). Mutant embryos also ex-
pressed normal levels of Brg1-associated factors (BAFs),
which are noncatalytic subunits of SWI/SNF-related
Figure 2. Molecular nature of the
Brg1ENU1 mutation. (A) DNA sequences of
wild-type (WT) and Brg1ENU1 (Mut) RT–
PCR products are displayed showing an A-
to-G point mutation, resulting in a glu-
tamic acid (Glu, E)-to-glycine (Gly, G)
amino acid substitution. (B, top) A sche-
matic of the Brg1 protein, indicating the
position of the E1083G amino acid substi-
tution between putative helicase motifs IV
and V of the catalytic ATPase domain.
(ZFP) Zinc-finger protein interaction do-
main; (Rb) retinoblastoma protein interac-
tion domain. (Bottom) Amino acid se-
quence alignment showing Homo sapiens
and Mus musculus Brg1 E1083 and adja-
cent residues compared with H. sapien/
M. musculus Brm, D. melanogaster BRM,
and S. cerevisiae SWI2 and STH1 within
the SWI2/SNF2 subfamily, as well as H.
sapien/M. musculus Snf2l and Etl1 and S.
cerevisiae RAD54 outside the SWI2/SNF2
subfamily. E1083 and corresponding resi-
dues are highlighted with a yellow vertical
bar. Identities are represented by dots.
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complexes (see Mut lanes under Input heading of West-
ern blot panels in Fig. 3B). In addition, the Brg1ENU1 pro-
tein was shown to physically interact with BAFs in co-
immunoprecipitation assays using a BRG1 antibody that
does not cross-react with BRM (see Mut lanes under
Brg1 IP heading of Western blot panels in Fig. 3B; see
Supplementary Fig. 1 for specificity of BRG1 antibody).
This finding indicated that SWI/SNF-related complexes
assemble and are stable in mutants. In these experi-
ments, a mock immunoprecipitation was performed,
where BRG1 antibody was omitted from wild-type em-
bryo lysates, as a negative control. Complete lack of sig-
nal demonstrated that Protein A/G agarose beads did not
bind Brg1 or BAFs nonspecifically (see Mock lanes in
Western blot panels of Fig. 3B).
Next, we wanted to determine whether mutant com-
plexes exhibit reduced ATPase activity. We isolated na-
tive SWI/SNF-related complexes by coimmunoprecipita-
tion using a BRG1 antibody that does not cross-react
with BRM as before. Western blot analyses indicated
that equivalent amounts of wild-type and mutant Brg1
were recovered (data not shown), and ATPase assays
were performed directly on agarose beads. Hydrolyzed
[32P]Pi was separated from [32P]ATP on cellulose
plates by thin layer chromatography (Fig. 3C) and quan-
tified by densitometry (Fig. 3D). Wild-type controls and
mutants had similar ATPase activities (Fig. 3C,D).
ATPase activity was stimulated by DNA as expected for
SWI/SNF (data not shown). The high degree of similarity
between wild-type and mutant ATPase activities was
surprising because Brg1 is the catalytic subunit and the
E1083G substitution lies within the ATPase domain. To
reconcile this apparent paradox, additional ATPases
were included in the amino acid sequence alignment
(Fig. 2B). Importantly, although E1083 is absolutely con-
served from yeast to human within the SWI2/SNF2 sub-
family, it is not conserved in closely related proteins
(e.g., Snf2l and Etl1) or more distantly related members
of the ATPase superfamily (e.g., RAD54) (Eisen et al.
1995). Based on this observation and X-ray crystal struc-
tures of the catalytic domain from related proteins (Durr
et al. 2005; Thoma et al. 2005), E1083 cannot be part of
the active site. Instead, E1083 is part of a SWI2/SNF2
subfamily signature that might be involved in determin-
ing how the energy of ATP hydrolysis is harnessed to
change the conformation and position of nucleosomes.
Brg1null/ENU1 erythropoiesis defect
The increased penetrance of Brg1null/ENU1 lethality from
E11.5 to E14.5 (Supplementary Table 1) coincides with
erythropoiesis switching from the yolk sac to the fetal
liver. The main switch occurs at E11.5, but yolk sac-
derived erythrocytes persist and continue to circulate for
several days. Accordingly, these primitive erythrocytes
account for nearly all of the peripheral red blood cells at
E10.5 but drop to 75% at E12.5 and 10% by E14.5
(Mucenski et al. 1991; Trimborn et al. 1999). There is
normally a concomitant increase in fetal liver-de-
rived definitive erythrocytes in the general circulation
from very few at E10.5 to 25% at E12.5 and 90% by
E14.5. However, this switch did not occur properly in
Brg1null/ENU1 embryos, hereafter referred to as mutants,
which led to severe anemia and death. Mutants still alive
at E12.5 exhibited signs of normal primitive erythropoi-
esis in the yolk sac (Fig. 4A) but greatly diminished de-
finitive erythropoiesis in the fetal liver (Fig. 4B). Mutant
fetal livers had either a red speckled appearance or were
Figure 3. Normal stability and ATPase activity of mutant
SWI/SNF-related complexes. (A) Brg1 mRNA and protein ex-
pression. (Top) Northern blot of wild-type (WT) and mutant
(Mut) E12.5 embryo RNAs hybridized with Brg1 and Actin con-
trol probes. (Bottom) Western blot of E12.5 embryo protein ly-
sates probed with BRG1 and Actin control antibodies. (B) Co-
immunoprecipitation of BAFs from wild-type (WT) and mutant
(Mut) E12.5 embryo protein lysates. Shown are Western blot
panels containing input protein (under Input heading), proteins
coimmunoprecipitated with a BRG1 antibody (under Brg1
IP heading), and a mock coimmunoprecipitation where BRG1
antibody was omitted but Protein A/G-conjugated agarose
beads were added to wild-type protein lysates and processed
(Mock). Western blot panels were probed with antibodies spe-
cific for BAF250, BRG1, BAF155, BAF57, and BAF47. IgG heavy-
chain bands (∼55 kDa) are visible in IP lanes of the BAF57 panel.
(C) ATPase assay. Wild-type (WT) and mutant (Mut) SWI/SNF-
related complexes, isolated from E12.5 embryos by coimmuno-
precipitation using a BRG1-specific antibody, were incubated
with radiolabeled ATP, and reactions were subjected to thin-
layer chromatography. Hydrolyzed [32P]Pi and unhydrolyzed
[32P]ATP and are indicated on the right. Two negative controls
are shown: (Mock) Mock immunoprecipitation as described
above; (Neg) no protein added to radiolabeled ATP reaction mix-
ture. (D) Quantification of ATPase assays. Densitometry was
used to measure [32P]Pi and [32P]ATP values. The ratio of
[32P]Pi to [32P]ATP was calculated and the negative control
background signal was subtracted. Wild-type samples were nor-
malized to 100%. The experiment was repeated three times, and
error bars are shown.
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completely pale, indicating a lack of hemoglobin-con-
taining cells. We stained cytospin preparations of fetal
liver cells with Wright-Giemsa to determine which cell
types were present or absent (Fig. 4C). Wild-type controls
had erythroid cells at each stage of the lineage. These
cells ranged from proerythroblast progenitors, through a
series of increasingly differentiated erythroblasts that be-
come progressively smaller with nuclei that are smaller
and more condensed, to enucleated reticulocytes (Fig.
4C,D). Nucleated yolk sac-derived erythrocytes were
also present as expected. In contrast, mutants had pro-
erythroblasts and basophilic erythroblasts but lacked
more mature polychromatic erythroblasts, orthochro-
matic erythroblasts, and enucleated reticulocytes (Fig.
4D). An arrest at this stage in the lineage explains the
extreme pallor of mutant fetal livers because hemoglo-
bin begins to accumulate at significant levels in poly-
chromatic erythroblasts (Wojda et al. 2002). Nucleated
yolk sac-derived erythrocytes and megakaryocytes were
present in mutant fetal livers (Fig. 4D), indicating that
the defect was restricted to definitive erythropoiesis.
Flow cytometry was performed to confirm and extend
the previous histological findings. Using forward scatter
as a measure of cell size, a broad distribution of fetal liver
cell sizes was observed in wild-type controls, whereas
smaller, more differentiated cells were underrepresented
in mutants (Fig. 4E). Kit and Ter119 cell-surface markers
were utilized to identify specific classes of cells in a
quantitative manner. Kit is a progenitor cell marker
(Uoshima et al. 1995), and Ter119 is a pan-erythroid
marker (Fig. 4C; Kina et al. 2000). Therefore, Kit-positive
cells represent hematopoietic stem cells (HSC), ery-
throid burst forming units (BFU E), and erythroid colony
forming units (CFU E). Kit/Ter119 double-positive cells
correspond to proerythroblasts and basophilic erythro-
blasts. Ter119-positive cells represent terminally differ-
entiated polychromatic erythroblasts, orthochromatic
erythroblasts, and enucleated reticulocytes (and nucle-
ated yolk sac-derived erythrocytes). Finally, double-nega-
tive cells include nonerythroid hematopoietic cells, fi-
broblasts, and hepatocytes. The percentage of Kit, Kit/
Ter119, Ter119, and double-negative cells in wild-type
fetal livers was 10%, 25%, 60%, and 5%, respectively
(Fig. 4F). In mutants, the Ter119 class was markedly re-
duced, from 60% to 5% (Fig. 4F). Moreover, most or all of
these cells were probably yolk sac derived, since they
also express Ter119. On the other hand, Kit (32%) and
Kit/Ter119 progenitor cells (52%) were well represented
Figure 4. Brg1null/ENU1 erythroid phenotype. (A,B) Bright-field photographs of wild-type control (left) and mutant (right) E12.5 em-
bryos inside of yolk sacs (A) and with yolk sacs removed (B). (C) Schematic of erythroid lineage. (HSC) Hematopoietic stem cell;
(BFU-E) erythroid burst-forming unit; (CFU-E) erythroid colony-forming unit; (E) proerythroblast; (B) basophilic erythroblast;
(P) polychromatic erythroblast; (O) orthochromatic erythroblast; (N) enucleated reticulocyte. Expression status of Kit and Ter119
cell-surface markers utilized for flow cytometric anlayses in panel F are indicated below. (D) Cystospin preparations of wild-type (top)
and mutant (bottom) fetal liver cells stained with Wright-Giemsa. Abbreviations are the same as for panel C except for two additions:
(Y) yolk sac derived erythrocyte; (M) megakaryocyte. Megakaryocytes were present in wild-type fetal livers but none are shown in the
upper panel. (E) Flow cytometry of wild-type (top) and mutant (bottom) fetal liver cells showing forward scatter versus side scatter.
Arrows point to smaller, more mature population of erythroid cells that were well represented in wild type but underrepresented in
mutants. (F) Distribution of Kit and Ter119 wild-type (top) and mutant (bottom) E12.5 fetal liver cells. (Upper left quadrants)
Kit-positive cells. (Upper right quadrants) Kit/Ter119 double-positive cells. (Lower right quadrants) Ter119-positive cells. (Lower left
quadrants) Double-negative cells. Percentage of cells in each quadrant is indicated.
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in Brg1 mutants (Fig. 4F), consistent with the Wright-
Giemsa-stained cytospin results. Double-negative cells
were also well represented (11%). However, each of these
cell types was overrepresented only on a percentage basis
as a consequence of mutants having so few Ter119-posi-
tive cells. Therefore, mutant progenitor cells were not
accumulating or piling up in the lineage upstream of the
developmental block. Taken together, the Wright-
Giemsa-stained cytospin results and flow cytometry
data indicate mutant progenitor cells arrest at the baso-
philic-to-polychromatic erythroblast transition. Interest-
ingly, EKLF and GATA-1 mutants exhibit a similar ar-
rest at the proerythroblast stage (Fujiwara et al. 1996;
McDevitt et al. 1997; Drissen et al. 2005).
Brg1 versus Brm expression in the erythroid lineage
We were curious why most tissues and organ systems
developed properly in Brg1null/ENU1 mutants, consider-
ing that Brg1 encodes a chromatin-modifying factor ex-
pressed in a widespread manner. One possible explana-
tion was that the Brm paralog could functionally com-
pensate everywhere except in the erythroid lineage. Brm
is 75% identical to Brg1 at the amino acid level, has
identical activities in several in vitro assays, and is also
broadly expressed. Expression of these two genes has not
been compared in the erythroid lineage, so we performed
RT–PCR on Ter119-positive flow sorted cells. Although
both Brg1 and Brm were expressed in whole embryos,
which served as a positive control, only Brg1 was ex-
pressed in Ter119-positive cells (cf. Brg1 and Brm panels
for Ter119 lane in Fig. 5). Gapdh was amplified to dem-
onstrate that the Ter119-positive cells and other RT
templates were of good quality and present in equivalent
amounts. An Epor control amplicon confirmed that
Ter119-positive cells were, in fact, erythroid. These re-
sults support the notion that Brm may compensate in
many cell types but cannot do so in the erythroid lineage
because it is not expressed. We propose that Brg1 and
SWI/SNF-related complexes are particularly important
at the basophilic-to-polychromatic erythroblast transi-
tion because the genome is becoming highly condensed
but certain genes must be maintained in an open chro-
matin configuration and continue to be expressed. A
similar proposal has been made regarding the role of
SWI/SNF complexes regulating gene expression while
the chromosomes are highly condensed during mitosis
in yeast (Krebs et al. 2000).
We also compared Brg1 and Brm expression in several
other hematopoietic lineages (Fig. 5). Brg1 was robustly
expressed in all of the lineages that were analyzed. In
contrast, Brm was differentially expressed with moder-
ate to relatively high levels of mRNA in T helper cells
(CD4+), cytotoxic T cells (CD8+), macrophages (Mac+),
and granulocytes (Gr+) but very low levels of mRNA in
immature, double-positive T cells (CD4+ CD8+) and in B
cells (B220+). The Brg1null/ENU1 mutant phenotype oc-
curs too early to assess either type of lymphocyte, but
Cre-loxP strategies have already demonstrated a role for
Brg1 in T-cell development (Chi et al. 2003; Gebuhr et al.
2003). In these studies, a developmental block was
shown to occur at the double-negative-to-double-posi-
tive transition, which coincides with lack of Brm expres-
sion in this lineage.
A Brg1 downstream target is the -globin locus
Gene expression profiling of Kit-positive cells flow
sorted from wild-type and mutant fetal livers identified 
globin as a downstream target gene (data not shown), and
this result was confirmed by RT–PCR. The expression of
both fetal/adult -globin genes, maj (Hbb-b1) and min
(Hbb-b2), was reduced in mutants (Fig. 6). In contrast, we
did not observe any difference in the expression of either
embryonic -globin gene (Y or H1) (Fig. 6). These re-
sults are consistent with the Brg1 mutant phenotype
(i.e., E11.5–E14.5 lethality). Y and H1 are expressed by
yolk sac-derived primitive erythrocytes (but not fetal
liver-derived definitive erythrocytes), and primitive
erythropoiesis defects usually result in lethality by
E10.5. maj and min are expressed by fetal liver-derived
definitive erythrocytes (but not yolk sac-derived primi-
tive erythrocytes), and definitive erythropoiesis defects
usually result in lethality at E11.5 or later in develop-
ment. These results indicate that globin switching oc-
curs normally in mutants, but definitive erythroblasts
express fetal/adult  globins at reduced levels.
Reduced -globin transcription is consistent with pre-
vious in vitro data. The zinc-finger transcription factors
EKLF and GATA-1 bind directly to Brg1 (but not Brm),
and EKLF can recruit SWI/SNF-related complexes to the
-globin locus in erythroleukemia cell lines (Armstrong
Figure 5. Brg1 and Brm expression in erythroid cells and other
hematopoietic lineages. Shown are negative images of ethidium
bromide-stained agarose gels of Brg1 and Brm RT–PCR products
amplified from the following flow-sorted cell populations:
(CD4+) T helper lymphocytes; (CD8+) cytotoxic T lympho-
cytes; (CD4+ CD8+) immature double-positive T lymphocytes;
(Mac1+) macrophages; (Gr1+) granulocytes; (Ter119+) erythroid
(highlighted with a vertical arrowhead); (B220+) B lymphocytes.
Two controls were also performed: (Embryo) E12.5 positive con-
trol; (Neg) no template negative control. In addition to Brg1 and
Brm, two control amplicons were included: (Gapdh) glyceralde-
hyde 3-phosphate dehydrogenase; (Epor) erythropoietin recep-
tor, to control for specificity of Ter119 erythroid marker.
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et al. 1998; O’Neill et al. 1999; Kadam and Emerson
2003). This recruitment step and Brg1 ATPase activity
are necessary to establish DNase I hypersensitive sites
(HSs) characteristic of open chromatin and stimulate
transcription of a -globin reporter construct (Armstrong
et al. 1998).
Perturbed chromatin remodeling at the -globin locus
We performed a series of experiments to investigate the
role of Brg1 and SWI/SNF-related complexes in the regu-
lation of the -globin locus in vivo. The mouse -globin
LCR consists of a series of tissue-specific DNase I HSs
that have enhancer and possibly insulator or boundary
element properties in the erythroid lineage. The LCR
directs transcription of four downstream -globin genes
arranged in the order of their developmental expression
(Fig. 7A). EKLF and GATA-1 bind to their consensus se-
quences (CACCC and A/TGATAA/G, respectively) in
HS2 and HS3 (Lee et al. 2000; Duan et al. 2001; Horak et
al. 2002; Levings and Bungert 2002). Therefore, we first
wanted to determine whether Brg1 is recruited to these
sites in vivo as expected. We performed chromatin im-
munoprecipitation (ChIP) assays on E12.5 fetal liver cells
with a BRG1 antibody. Robust PCR products indicated
that Brg1 was localized to both HS2 and HS3 in wild-
type and mutant samples (see ChIP lanes for HS2 and
HS3 panels in Fig. 7B). The finding that mutant Brg1 also
localized to HS2 and HS3 is consistent with the point
mutation (E1083G) not disrupting the N-terminal EKLF/
GATA-1 interaction domain (corresponding to ZFP
in Fig. 2B) but rather lying in the ATPase domain.
Mock immunoprecipitations were also performed,
where BRG1 antibody was omitted, to serve as a negative
control. Complete lack of HS2 and HS3 PCR products
demonstrated that Protein A/G agarose beads were not
binding Brg1 or HS2/HS3 nonspecifically (see M lanes in
Fig. 7B). As an additional negative control, we attempted
to amplify the promoter of a gene (Necdin) not regulated
by Brg1 from the same ChIP templates. Unlike the HS2
and HS3 results, Brg1 was not localized to this promoter
(see ChIP lanes for Necdin promoter panel in Fig. 7B).
Considering that mutant SWI/SNF-related complexes
localize to the -globin locus, we wanted to test whether
chromatin structure was affected. Therefore, DNase I
hypersensitivity assays were performed to compare the
chromatin structure of the LCR in wild-type and mutant
embryos. Fetal liver cells were harvested, nuclei were
digested with DNase I, DNA was subsequently purified,
and five out of the six HSs were amplified by PCR. HS5
was excluded from this analysis because it is a relatively
weak site in the mouse (Bender et al. 1998). As wild-type
nuclei were digested with increasing concentrations of
DNase I, more DNA molecules were cleaved, fewer PCR
templates remained intact, and PCR product yields de-
clined (Fig. 7C). These data indicate the LCR was in an
open chromatin configuration as expected. In mutant
nuclei, increasing DNase I concentrations had less of an
effect and PCR product yields were greater than the cor-
responding controls for each HS amplicon (Fig. 7C).
These data indicate that the LCR in mutants was not as
accessible to DNase I because of unusually condensed
chromatin. To rule out the possibility that different
amounts of wild-type and mutant DNAs were recovered
from DNase I-treated nuclei, all of the samples had an
Mit marker that is relatively resistant to DNase I ampli-
fied as a control (Fig. 7C).
It has been known for a long time that Brg1 ATPase
activity is required for SWI/SNF function, but it still is
not clear how the energy of ATP hydrolysis is harnessed
to change the conformation and position of nucleo-
Figure 6. Expression of -globin genes. (A)
Shown are images of ethidium bromide-
stained agarose gels containing Actin and
-globin RT–PCR products amplified from
wild-type (WT) or mutant (Mut) E12.5 fetal
livers. For each panel, the upper band is Ac-
tin and the lower band is a -globin (the
positions of which are indicated with ar-
rowheads). The individual  globin ampli-
cons are, from left to right, maj, min, Y,
and H1. For the Y and H1 panels, two
templates were used: (1) Fetal livers; (2) Kit-
positive cells from fetal livers that were iso-
lated by flow sorting. Expression of both
embryonic globins can be observed in wild-
type and mutant fetal livers because of yolk
sac-derived primitive erythocytes still in
the general circulation (see 1s). In contrast,
neither embryonic globin is ectopically ex-
pressed in mutant Kit-positive definitive
erythroblasts (see 2s). (MW) One-kilobase
molecular weight standard. (B) Quantifica-
tion of -globin expression levels. For wild-
type samples (black bars), ratios of  globin
to actin were normalized to 100%. Mutant samples (gray bars) were expressed as a percentage relative to wild type. Y and H1 values
are based on fetal liver data (1s from A).
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somes. The Brg1ENU1 mutation may provide insight into
this mechanism since ATPase activity (which is normal,
see Fig. 3C) is uncoupled from chromatin remodeling
(which is abnormal, see Fig. 7C). It is interesting to note
that deletion of putative helicase motif V in yeast SWI2/
SNF2 (72 residues downstream) also uncouples ATPase
activity from chromatin remodeling (even though a ly-
sine residue two amino acids upstream of E1083 is re-
quired for ATPase activity) (Smith and Peterson 2005).
Point mutations in putative helicase motif V of BRG1
seem to be overrepresented in primary tumors and tumor
cell lines, which lends credence to the importance of this
energy transduction mechanism (Wong et al. 2000; Me-
dina et al. 2004; Smith and Peterson 2005).
Altered histone acetylation and DNA methylation
at the LCR
More distantly related SNF2-like proteins, which are
presumably the catalytic subunits of other ATPase re-
modeling complexes, have been shown to influence co-
valent histone modifications or DNA methylation (Gib-
bons et al. 2000; Dennis et al. 2001; Meehan et al. 2001;
Pray-Grant et al. 2005). Less is known about Brg1 and
SWI/SNF-related complexes in this regard, so we evalu-
ated both types of epigenetic marks. First, we performed
ChIP assays to measure histone 3 (H3) acetylation levels
at the -globin LCR. We cross-linked and sonicated chro-
matin from fetal liver and head cells, immunoprecipi-
tated with an anti-pan-acetyl H3 antibody, reversed
the cross-links, prepared genomic DNAs, and amplified
HSs 1, 2, 3, 4, and 6. In wild-type embryos, each site
was acetylated in a tissue-specific manner. Robust acety-
lation was detected in erythroid cells of the fetal liver
with little or no background signal detected in nonery-
throid cells of the head (cf. FL and H ChIP lanes in
WT panels of Fig. 8A). Mock immunoprecipitations were
performed, where acetyl H3 antibody was omitted from
fetal liver ChIP assays, to serve as a negative control.
Complete lack of signal at each HS demonstrated
Figure 7. Chromatin structure is altered at the -globin locus. (A) Schematic of mouse -globin locus. The LCR consists of six HSs
(vertical arrows), although HS5 is a weak site in the mouse (denoted by thin vertical arrow). EKLF and GATA-1 bind to HS2 and HS3.
All four -globin genes consist of three exons (black boxes) that are transcribed in the same orientation and arranged in the order of
their developmental expression. (B) Recruitment of Brg1 to the -globin LCR. ChIP assays demonstrating that wild-type and mutant
Brg1 are recruited to HS2 and HS3. Shown are images of ethidium bromide-stained agarose gels of HS2, HS3, and a negative control
(Necdin promoter) amplified from wild-type (WT) or mutant (Mut) E12.5 fetal liver cells. (MW) One-kilobase molecular weight
standard (the 1- and 0.5-kb bands are visible); (Pos) wild-type genomic DNA served as a positive control for PCR; (Neg) no template
negative control; (Input) total chromatin, sheared but not immunoprecipitated; (ChIP) chromatin immunoprecipitated with a BRG1
antibody; (M) mock immunoprecipitation, which served as a negative control, where BRG1 antibody was omitted from wild-type
chromatin but processed in a manner identical to ChIP samples. (C) DNase I hypersensitivity assays of -globin LCR. Nuclei from
wild-type (WT) and mutant (Mut) E12.5 fetal liver cells were digested with increasing amounts of DNase I (from left to right: 0.01, 0.10,
0.50, 1.00, and 2.50 U of enzyme per microgram of DNA). Genomic DNA was subsequently prepared, and HSs 1, 2, 3, 4, and 6 were
PCR amplified. To correct for small differences in the amount of DNA that might have been recovered for each sample, an Mit marker
(D9Mit59) was amplified as a control (see CNTRL panel). (Pos) Wild-type genomic DNA served as a positive control for each amplicon;
(Neg), no template was used as a negative control for each amplicon. Each panel is an image of PCR products run on an ethidium
bromide-stained agarose gel. (MW) One-kilobase Plus molecular weight standard (bands from 1 kb to 100 bp are visible).
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that Protein A/G agarose beads were not binding acetyl
H3 or any of the HSs nonspecifically (see Neg. lanes in
Fig. 8A). In mutant embryos, none of the HSs were acety-
lated at normal levels. Instead, mutant fetal livers had
either no signals or faint signals comparable to back-
ground levels observed in head tissue (cf. FL and H ChIP
lanes in Mut panels in Fig. 8A). Chromatin prepared
from head tissue was of good quality (cf. FL and H Input
lanes in Fig. 8A) and capable of being H3 acetylated based
on enrichment of this mark at the promoter of a gene
(Necdin) expressed in neurons and other cell types (see
Necdin panel in Fig. 8A; Uetsuki et al. 1996; Forsberg et
al. 2000).
Second, we analyzed DNA methylation at a genome-
wide level and at the -globin LCR. To evaluate genome-
wide DNA methylation, we prepared genomic DNA
from wild-type and mutant embryos, digested with Hpa
II or Msp I restriction enzymes, and separated the DNA
fragments by size on agarose gels. Hpa II and Msp I rec-
ognize the same DNA sequence (CCGG) but are isoschi-
zomers. Hpa II is methylation sensitive and cuts rela-
tively infrequently, whereas Msp I is methylation insen-
sitive and cuts much more often, giving rise to smearing
of lower molecular weight fragments. We did not observe
any difference between the wild-type and mutant digests
(Fig. 8B), suggesting that genome-wide methylation is
normal in mutants.
To evaluate DNA methylation at the -globin LCR,
we performed sodium bisulfite mutagenesis on wild-type
and mutant fetal liver DNAs, PCR amplified HS1 and
HS2, subcloned the PCR products, and sequenced indi-
vidual subclones. HS1 and HS2 each contain two CpGs.
All four CpGs were unmethylated in wild-type controls
but partially methylated in mutants (Fig. 8C). Therefore,
although mutant tissues apparently had normal ge-
nome-wide methylation levels, methylation of specific,
physiologically relevant targets were altered. Similarly,
BRG1-deficient tumor cells display aberrant methyl-
ation at a specific locus (but not the entire genome) that
can be rescued by transfection of a BRG1 expression vec-
tor (Banine et al. 2005). Although it is not clear how the
energy of ATP hydrolysis is harnessed to change the con-
formation and position of nucleosomes, histone acetyla-
tion and DNA methylation might be part of the mecha-
nism since both are affected as a consequence of the
E1083G substitution.
Discussion
Here, we present the characterization of a novel, ENU-
induced Brg1 mutation (Brg1ENU1) that results in a single
amino acid substitution (E1083G) in the catalytic
ATPase domain. Not only is the mutant protein stable
and capable of assembling into SWI/SNF-related com-
plexes, it also exhibits normal ATPase activity. The no-
tion that E1083 does not comprise part of the ATPase-
active site is supported by the fact that this residue is not
conserved in proteins outside of the SWI2/SNF2 subfam-
ily as well as its predicted position in X-ray crystal struc-
tures (Durr et al. 2005; Thoma et al. 2005).
Brg1null/ENU1 embryos develop normally until midges-
tation when erythropoiesis switches from the yolk sac
(i.e., primitive erythropoiesis) to the fetal liver (i.e., de-
finitive erythropoiesis). A defect in definitive erythropoi-
Figure 8. Aberrant epigenetic modifica-
tions at the -globin locus. (A) ChIP assays
showing histone 3 (H3) acetylation status
at the -globin LCR. Shown at the left are
images of ethidium bromide-stained aga-
rose gels containing HSs 1, 2, 3, 4, and 6
amplified from wild-type (WT) or mutant
(Mut) E12.5 tissues. Necdin promoter was
also amplified as a control because it cor-
responds to the promoter of a gene (Nec-
din) that is acetylated and expressed in
neurons and other cell types. (Pos) Wild-
type genomic DNA served as a positive
control for PCR; (Neg) negative control,
mock immunoprecipitation where no an-
tibody was added to wild-type FL chroma-
tin but processed in a manner identical to
ChIP samples; (Input) total chromatin,
sheared but not immunoprecipitated, pre-
pared from fetal liver (FL) or head (H) cells;
(ChIP) FL or H chromatin immunoprecipi-
tated with an anti-acetyl H3 antibody.
Shown at the right is quantification of the
ChIP data utilizing digitized images of the gels. ChIP band intensities were divided by Input band intensities after subtracting out
background levels. Values were normalized to 100% for wild-type samples (black bars). Mutant samples (gray bars) were expressed as
a percentage of wild-type values. (B) Genome-wide DNA methylation analysis. Image of an ethidium bromide-stained agarose gel of
wild-type (WT) and mutant (Mut) genomic DNAs digested with Hpa II (H) or Msp I (M). (MW) One-kilobase ladder molecular weight
standard. (B) Sodium bisulfite mutagenesis analysis of HS1 and HS2 within -globin LCR of wild-type and mutant fetal liver cells.
(Unfilled circles) Unmethylated CpGs; (filled circles) methylated CpGs.
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esis leads to anemia and death between E11.5 and E14.5.
In mutant fetal livers, erythroid progenitors develop nor-
mally until a block occurs at the basophilic-to-polychro-
matic erythroblast transition. Brg1 and SWI/SNF-related
complexes might be particularly important at this stage
in the lineage because the nucleus is becoming increas-
ingly condensed but certain genes must be maintained in
an open chromatin configuration and continue to be ex-
pressed.
Although the erythroid lineage is severely affec-
ted, most other tissues/organs develop normally in
Brg1null/ENU1 mutants. This finding can possibly be ex-
plained by our finding that although Brm is expressed in
a widespread manner, it is not expressed in the erythroid
lineage. Brm can therefore be expected to compensate in
most tissues but not the erythroid lineage.
At a mechanistic level, the zinc-finger transcription
factors EKLF and GATA-1 bind Brg1 (Kadam and Emer-
son 2003) and can recruit wild-type as well as mutant
SWI/SNF-related complexes to the -globin LCR. Once
recruited, Brg1 is required for the LCR to adopt an open
chromatin structure. Although Brg1 ATPase activity is
necessary for function, our results indicate that it is not
sufficient. The E1083G substitution may be revealing a
segment of the ATPase domain involved in harnessing
the energy derived from ATP hydrolysis to alter the con-
formation and position of nucleosomes. In Brg1 mutants,
the LCR is not H3 acetylated and CpGs are methylated.
The LCR adopts a closed chromatin configuration, -glo-
bin transcription is reduced, and definitive erythroblasts
undergo developmental arrest instead of terminal differ-
entiation. This arrest occurs at a stage when -globin
transcription is normally peaking (Wojda et al. 2002) de-
spite the onset of nuclear condensation.
Materials and methods
ENU mutagenesis
One gram of ENU (Sigma) was dissolved in 10 mL of 95% etha-
nol and mixed with 90 mL of phosphate/citrate buffer (0.1 M
dibasic sodium phosphate, 0.05 M citrate at pH 5.0) while keep-
ing glassware wrapped in aluminum foil to minimize light ex-
posure. To determine concentration, 200 µL of ENU was diluted
to 1 mL with phosphate/citrate buffer (1:5 dilution), transferred
to disposable cuvettes, and measured in a spectrophotometer at
OD398. (OD398/0.72) (5) = X mg/mL. Eight-week-old to 12-wk-
old male mice received three weekly intraperitoneal (IP) injec-
tions at a dose of 100 mg/kg body weight.
Blots
Northern and Western blots were performed according to stan-
dard procedures (Ausubel et al. 1992). The Brg1 Western blots
utilized a mouse monoclonal raised against the N-terminal por-
tion of human BRG1 that does not cross-react with BRM (a gift
from P. Chambon, Institut Clinique de la Souris [ICS], Ippkirch,
France). The BAF antibodies were rabbit polyclonals (a gift from
G. Crabtree [Howard Hughes Medical Institute, Department of
Developmental Biology, Stanford University, Stanford, CA] and
W. Wang [Laboratory of Genetics, National Institute on Aging,
National Institute of Health, Geontology Research Center, Bal-
timore, MD]). Primary antibodies were detected using goat anti-
mouse or anti-rabbit secondary antibodies conjugated to horse-
radish peroxidase.
Immunoprecipitations
E12.5 embryos were placed in RIPA buffer (100 mM NaCl, 20
mM Tris at pH 7.6, 0.2% deoxycholate, 0.2% Triton X-100,
0.2% NP40) containing DTT (1 mM), -mercaptoethanol (2
mM), and protease inhibitors. Tissues were sonicated twice at
70% amplitude on wet ice and spun at 3500 rpm for 30 min at
4°C to pellet debris. The concentrations of protein lysates were
determined by Bradford assays. Approximately 1 mg of protein
was immunoprecipitated with 4 µg of a mouse monoclonal an-
tibody raised against the N-terminal portion of human BRG1
that does not cross-react with BRM (Santa Cruz). This step went
overnight at 4°C while rocking on a nutator. Fifty microliters of
preblocked Protein G (Oncogene) or Protein A/G (Santa Cruz)
agarose beads were added, and the incubation continued for
three more hours. Samples were washed two times in IP0.2
buffer (20 mM HEPES at pH 7.6, 10% glycerol, 12.5 mM MgCl2,
0.1 mM EDTA at pH 8.0, 0.2% NP40, 0.1 mM DTT, 0.6 M
KOAc) and processed immediately or stored at −80°C.
ATPase assays
Twenty-microliter reactions were carried out directly on aga-
rose beads in 10 mM Tris (pH 7.5), 50 mM NaCl, 5 mM MgCl2,
20% glycerol in the presence of BSA (1 mg/mL), PMSF (0.5 mM),
DTT (1mM), ATP (0.5mM), plasmid DNA (20 nM), and 1 µCi
[32P]-ATP at 37°C. Reactions were stopped by adding 1 µL of
0.5 µM EDTA and placing on wet ice. One microliter of each
reaction was spotted onto polyethyleneimine cellulose TLC
plates (Sigma), which had been prerun in distilled water and
dried. Inorganic phosphate was separated from uncleaved ATP
by running the TLC plates in 1 M formic acid and 0.5 M LiCl in
a glass TLC developing tank. The ratio of inorganic phos-
phate to ATP was quantified using a Molecular Dynamics
Phosphorimager (Amersham Biosciences) and ImageQuant soft-
ware.
Cytospin preparations
Fetal livers were triturated in PBS containing 2% FBS using 1-cc
syringes fitted with needles having progressively smaller aper-
tures (18, 22, and 25 gauges). Two hundred microliters of the
single-cell suspensions were added to cuvettes assembled with
paper pads and microscope slides (that were pretreated with
PBS/FBS) in metal holders. Samples were spun at 700 rpm for 10
min, air dried, fixed in methanol for 2 min, stained in Wright’s
stain (200 mL of Wright’s stain from Sigma mixed with 200 mL
methanol) for 4 min, stained in Giemsa buffer (11 mL of Giemsa
stain from Sigma freshly mixed with 50 mL distilled water) for
12 min, and dipped five times in 20% methanol followed by five
times in distilled water.
Flow cytometry
Fetal liver cell suspensions were prepared as described for cyto-
spins. Approximately 1 × 106 cells were incubated with anti-
Ter119-PE (Pharmingen) and anti-Kit-FITC (Pharmingen) on
wet ice in the dark for 1 h. Cells were washed several times,
fixed in 200 µL 2% PFA, and analyzed using a FACScan instru-
ment (Bectin Dickinson). For each experiment, wild-type cells
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were also incubated with Ter119-PE only, Kit-FITC only, or no
antibody to serve as compensation controls.
RT–PCR
RNA was prepared from E12.5 embryos, fetal livers, or flow-
sorted cell populations using Trizol reagent (Invitrogen) and re-
verse transcribed using random hexamers or Oligo d(T) and
SuperScript II RT (Invitrogen) according to standard procedures
(Ausubel et al. 1992). The Brg1 and Brm primers and amplifica-
tion conditions have already been described (Bultman et al.
2000). The Epor primers were 5-TGAGCTTCCTGAAGCTA
GGG-3 and 5-TCGCTAGCGGTCAGTAGTGA-3. The 765-
base-pair (bp) Epor product was amplified at 1 mM MgCl2 and a
55°C annealing temperature. For the -globin expression analy-
ses, the maj primers were 5-CGTTTGCTTCTGATTCTG
TTG-3 and 5-CTAGATGCCCAAAGGTCTTC-3, and the
corresponding product was 590 bp. The min primers were 5-
AAAGGTGAACCCCGATGAAG-3 and 5-TGTGCATAGA
CAATAGCAGA-3, and the corresponding product was 411 bp.
The Y primers were 5-TGACACTCCTGTGATCACCA-3
and 5-AAAGGAGGCATAGCGGACAC-3, and the corre-
sponding product was 535 bp. The H1 primers were 5-TCTC
CAAGCTTCTATACCTC-3 and 5-CATGGGATTGCCAGT
GTACT-3, and the corresponding product was 498 bp. All of
the -globin amplicons were amplified for 30 cycles at a 1 mM
MgCl2 concentration. The 
maj and min had a 61°C annealing
temperature, whereas the Y and H1 had a 55°C annealing
temperature. The actin control amplicon (5-CAAGGTGT
GATGGTGGGAAT-3 and 5-GGTGTAAAACGCAGCTCA
GT-3) was 1038 bp and worked at both 61°C and 55°C.
ChIP assays
The ChIP protocol was adapted from Upstate (http://www.up-
state.com) and Forsberg et al. (2000). Single cell suspensions
were prepared from E12.5 fetal livers as described above for
cytospin preparations. Protein–protein and protein–DNA inter-
actions were cross-linked in 0.4% formaldehyde at room tem-
perature for 10 min and stopped by adding glycine to a final
concentration of 0.125 M. Aliquots of 2 × 106 cells were lysed in
200 µL SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris at
pH 8.1, protease inhibitors), and chromatin was sonicated with
four 10-sec pulses at 30% of maximum power. Samples were
diluted to 2 mL with IP dilution buffer (0.01% SDS, 1.1% Triton
X-100, 1.2 mM EDTA, 16.7 mM Tris at pH 8.1, 167 mM NaCl,
protease inhibitors). One hundred microliters was removed as
input, and the remainder was processed for immunoprecipita-
tions. J1 antibody (a gift from G. Crabtree and W. Wang) was
used for Brg1, and anti-pan-acetyl H3 (Upstate) was used for
histone acetylation. Following overnight incubation at 4°C, pro-
tein A/G agarose beads (Santa Cruz) were added and incubated
for at least 2 h at 4°C. Samples were washed in low salt buffer,
high salt buffer, LiCl buffer, and TE and then eluted in elution
buffer (Forsberg et al. 2000). Cross-links were reversed with 0.2
M NaCl overnight at 65°C. DNA was purified by Proteinase K
treatment, phenol/chloroform extractions, and ethanol precipi-
tations. DNAs were resuspended in 25 µL and PCR amplified.
The HS 1, 2, 3, 4, and 6 oligonucleotide primers that were used
have already been described (McArthur et al. 2001). The Necdin
promoter oligonucleotide primers have also been described
(Forsberg et al. 2000).
DNase I hypersensitivity assays
Single cell suspensions were prepared from E12.5 fetal livers as
described above for cytospin preparations. The DNase I hyper-
sensitivity assays were performed as described (McArthur et al.
2001). The same HS 1, 2, 3, 4, and 6 oligonucleotide primers
were used as described (McArthur et al. 2001). The D9Mit59
control primers were 5-CAGCCAGAGGCAGTGTTTTA-3
and 5-TAGGCTTCAGCTGCAACTCA-3.
Sodium bisulfite mutagenesis
Genomic DNA (2.5 µg) was digested with the Sph I restriction
enzyme, extracted with phenol and chloroform, ethanol precipi-
tated, and resuspended in 50 µL TE. DNA was denatured in 0.3
N NaOH at 42°C for 30 min and then mutagenized in sodium
bisulfite (2.9 M) and hydroquinone (0.5 mM) at 55°C for ∼19 h
with minimal light exposure. DNA was purified using a ge-
nomic DNA purification kit (Promega), desulfonated with 0.3 N
NaOH treatment at 37°C for 15 min, neutralized with
NH4OAc, and ethanol precipitated. DNAs were ligated into the
pGem-T Easy vector (Promega) and transformed. Plasmid DNA
was prepared from individual ampicillin-resistant colonies (Qia-
gen miniprep kit) and sequenced.
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